BR112017020016A2 - formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao) - Google Patents
formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao)Info
- Publication number
- BR112017020016A2 BR112017020016A2 BR112017020016A BR112017020016A BR112017020016A2 BR 112017020016 A2 BR112017020016 A2 BR 112017020016A2 BR 112017020016 A BR112017020016 A BR 112017020016A BR 112017020016 A BR112017020016 A BR 112017020016A BR 112017020016 A2 BR112017020016 A2 BR 112017020016A2
- Authority
- BR
- Brazil
- Prior art keywords
- ssao
- salt forms
- oxidase inhibitor
- pharmaceutical salt
- amine oxidase
- Prior art date
Links
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 title 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 title 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- -1 sulfate salts (3s) -tetrahydrofuran-3-yl carboxylate Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507031.1A GB201507031D0 (en) | 2015-04-24 | 2015-04-24 | New pharmaceutical salt forms |
| PCT/GB2016/051119 WO2016170351A1 (en) | 2015-04-24 | 2016-04-22 | Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017020016A2 true BR112017020016A2 (pt) | 2018-06-19 |
Family
ID=53488629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017020016A BR112017020016A2 (pt) | 2015-04-24 | 2016-04-22 | formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10316034B2 (https=) |
| EP (1) | EP3286190B1 (https=) |
| JP (2) | JP2018513189A (https=) |
| KR (1) | KR20170139045A (https=) |
| CN (2) | CN112851669A (https=) |
| AR (1) | AR104360A1 (https=) |
| AU (1) | AU2016251707B2 (https=) |
| BR (1) | BR112017020016A2 (https=) |
| CA (1) | CA2979144A1 (https=) |
| DK (1) | DK3286190T3 (https=) |
| EA (1) | EA035668B1 (https=) |
| ES (1) | ES2804155T3 (https=) |
| GB (1) | GB201507031D0 (https=) |
| HU (1) | HUE049985T2 (https=) |
| IL (1) | IL254153A0 (https=) |
| MX (1) | MX2017013049A (https=) |
| PT (1) | PT3286190T (https=) |
| SG (1) | SG11201707867WA (https=) |
| WO (1) | WO2016170351A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
| GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
| GB201618029D0 (en) | 2016-10-25 | 2016-12-07 | Proximagen Ltd | New process |
| CN108017634A (zh) * | 2017-12-15 | 2018-05-11 | 清华大学 | 一种制备吡咯并多环衍生物的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141899A (en) | 1976-01-07 | 1979-02-27 | Societa' Farmaceutici Italia S.P.A. | 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives |
| IT1098015B (it) | 1978-08-07 | 1985-08-31 | Farmaceutici Italia | Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati |
| JP2002542245A (ja) * | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 置換イミダゾール、それらの製造および使用 |
| US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| WO2002038153A1 (en) * | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
| SE0004101D0 (sv) | 2000-11-09 | 2000-11-09 | Pharmacia Ab | New use |
| KR20060135781A (ko) * | 2004-02-25 | 2006-12-29 | 라 졸라 파마슈티칼 컴파니 | 질병의 치료를 위한 아민 및 아미드 |
| US20070066646A1 (en) | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
| EP3461499A1 (en) | 2006-06-07 | 2019-04-03 | The Board of Trustees of The Leland Stanford Junior University | Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures |
| US8633318B2 (en) * | 2008-09-16 | 2014-01-21 | Proximagen Ltd | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder |
| EP2334672B1 (en) * | 2008-09-16 | 2013-11-20 | Proximagen Limited | 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201115853D0 (en) * | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
| EP2755974A1 (en) * | 2011-09-14 | 2014-07-23 | Proximagen Limited | New enzyme inhibitor compounds |
| GB201304526D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| EP3131539B1 (en) | 2014-04-15 | 2018-12-05 | Pécsi Tudományegyetem | Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation |
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
| GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
-
2015
- 2015-04-24 GB GBGB1507031.1A patent/GB201507031D0/en not_active Ceased
-
2016
- 2016-04-22 JP JP2017555499A patent/JP2018513189A/ja active Pending
- 2016-04-22 CA CA2979144A patent/CA2979144A1/en not_active Abandoned
- 2016-04-22 PT PT167198928T patent/PT3286190T/pt unknown
- 2016-04-22 DK DK16719892.8T patent/DK3286190T3/da active
- 2016-04-22 EA EA201792121A patent/EA035668B1/ru not_active IP Right Cessation
- 2016-04-22 CN CN202110072000.2A patent/CN112851669A/zh active Pending
- 2016-04-22 WO PCT/GB2016/051119 patent/WO2016170351A1/en not_active Ceased
- 2016-04-22 KR KR1020177032022A patent/KR20170139045A/ko not_active Withdrawn
- 2016-04-22 AR ARP160101126A patent/AR104360A1/es unknown
- 2016-04-22 CN CN201680023326.3A patent/CN107531702A/zh active Pending
- 2016-04-22 MX MX2017013049A patent/MX2017013049A/es unknown
- 2016-04-22 AU AU2016251707A patent/AU2016251707B2/en not_active Ceased
- 2016-04-22 EP EP16719892.8A patent/EP3286190B1/en active Active
- 2016-04-22 ES ES16719892T patent/ES2804155T3/es active Active
- 2016-04-22 US US15/567,536 patent/US10316034B2/en active Active
- 2016-04-22 BR BR112017020016A patent/BR112017020016A2/pt not_active IP Right Cessation
- 2016-04-22 SG SG11201707867WA patent/SG11201707867WA/en unknown
- 2016-04-22 HU HUE16719892A patent/HUE049985T2/hu unknown
-
2017
- 2017-08-24 IL IL254153A patent/IL254153A0/en unknown
-
2021
- 2021-01-28 JP JP2021012044A patent/JP2021073256A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016251707B2 (en) | 2020-02-20 |
| AR104360A1 (es) | 2017-07-12 |
| PT3286190T (pt) | 2020-07-09 |
| JP2018513189A (ja) | 2018-05-24 |
| EP3286190B1 (en) | 2020-06-03 |
| US20180111928A1 (en) | 2018-04-26 |
| CN107531702A (zh) | 2018-01-02 |
| ES2804155T3 (es) | 2021-02-04 |
| MX2017013049A (es) | 2017-12-08 |
| CN112851669A (zh) | 2021-05-28 |
| US10316034B2 (en) | 2019-06-11 |
| WO2016170351A1 (en) | 2016-10-27 |
| EA035668B1 (ru) | 2020-07-23 |
| CA2979144A1 (en) | 2016-10-27 |
| IL254153A0 (en) | 2017-10-31 |
| DK3286190T3 (da) | 2020-07-13 |
| HK1249906A1 (en) | 2018-11-16 |
| AU2016251707A1 (en) | 2017-10-05 |
| SG11201707867WA (en) | 2017-11-29 |
| EP3286190A1 (en) | 2018-02-28 |
| JP2021073256A (ja) | 2021-05-13 |
| GB201507031D0 (en) | 2015-06-10 |
| KR20170139045A (ko) | 2017-12-18 |
| EA201792121A1 (ru) | 2018-03-30 |
| HUE049985T2 (hu) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45937A (fr) | Inhibiteurs d'amino pyrimidine ssao | |
| BR112017004141A2 (pt) | ?sondas para imageamento de proteína de huntingtina? | |
| EP3464809A4 (en) | DETECTION OF EVENTS IN HOLE HOLE REPORTS | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| CY1119645T1 (el) | Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης | |
| CO7091182A2 (es) | Inhibidores de beta-lactamasa isoxazol | |
| BR112019008415A2 (pt) | composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos | |
| DK3424920T3 (da) | Co-krystaller af (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinolin-4-carboxamid og deuterede derivater deraf som dna-pk-inhibitorer | |
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| BR112016020199A2 (pt) | Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| IL291191A (en) | Cdk inhibitors and their use as pharmaceuticals | |
| BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
| EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
| CL2016000556A1 (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso. | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| BR112017019653A2 (pt) | derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd | |
| BR112016009488A8 (pt) | piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica. | |
| BR112017020016A2 (pt) | formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao) | |
| BR112017004134A2 (pt) | ?sondas para imageamento de proteína de huntingtina? | |
| BR112017004136A2 (pt) | sondas para imageamento de proteína de huntingtina | |
| BR112016008799A8 (pt) | derivados de pirazolopirimidona ou pirrolotriazona, seus usos, seus processos para sua preparação e seus intermediários, e composição farmacêutica | |
| ITUA20161302A1 (it) | "dispositivo di rotazione e posizionamento in particolare per oggetti globosi" | |
| BR112017018342A2 (pt) | inibidores de grelina o-acil transferase | |
| BR112018072039A2 (pt) | composto, medicamento, método, e, uso do composto ou sal do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: BENEVOLENTAI CAMBRIDGE LIMITED (GB) |
|
| B25G | Requested change of headquarter approved |
Owner name: BENEVOLENTAI CAMBRIDGE LIMITED (GB) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2719 DE 14-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |